Yanuki
Health and Science / Pharmaceuticals
Pfizer (PFE) has released its Q4 2026 earnings, surpassing expectations despite a decrease in demand for its COVID-19 products. The company reaffirmed its financial outlook for 2026, emphasizing its long-term investments and cost-saving ini...
Finance / Earnings
Pfizer (PFE) has reported better-than-expected fourth-quarter earnings for 2026, navigating a decline in demand for its COVID-19 products through robust sales of established drugs and strategic investments in its pipeline. The pharmaceutica...
Finance / Investing
Pfizer Inc. (PFE) has seen significant activity from institutional investors and analysts recently. This article summarizes key transactions, dividend announcements, and the overall outlook for Pfizer stock in 2026.
Finance / Stocks
Pfizer (PFE) presents a compelling case for value investors, trading at a low valuation with a high dividend yield. However, concerns about upcoming patent expirations and revenue decline leave investors wondering: Is Pfizer an undervalued...
Finance / Stocks
Johnson & Johnson (JNJ) and Pfizer (PFE) are two pharmaceutical giants, but their stock performance has diverged significantly. JNJ has surged nearly 45% this year, while PFE has declined by 6%. This article examines the reasons behind this...
Finance / Stocks
Pfizer (NYSE: PFE) has faced headwinds with declining revenue and profits, leading to a drop in its stock value. However, recent developments, including strategic acquisitions and deals with the U.S. government, offer potential for a turnar...
Health / Policy
The Trump administration launched TrumpRx, aiming to lower prescription drug costs, but its impact remains uncertain compared to existing solutions like the Inflation Reduction Act.
Health / Weight Loss
Pfizer's $4.9 billion investment in Metsera is showing early promise. A Phase IIb trial of their obesity drug, MET-097i, has demonstrated a significant 14.1% weight loss in patients. This development positions Pfizer to be a strong contende...
Finance / Stocks
Pfizer's high dividend yield has attracted income investors, but patent expirations and pipeline uncertainties raise concerns about its long-term sustainability.
Finance / Company News
Pfizer (PFE) is navigating a complex market landscape. While some analysts urge caution due to potential overvaluation after a recent 'dead cat bounce', the company's oncology division is demonstrating robust growth, driven by key drugs and...
Finance / Earnings
Pfizer (PFE) is set to report earnings tomorrow, and analysts are keenly watching to see if the pharmaceutical giant can meet expectations amidst a complex market environment. This report arrives with mixed signals from previous performance...
Finance / Earnings
Analysts are approaching Pfizer's Q1 2025 earnings report with caution, citing patent expirations and competitive pressures. However, growth in non-COVID-related products offers a glimmer of optimism. The report is due on April 29th.
